Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse - sprookjes - yvandenbroek - TriplyDB

Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse

Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse

http://www.wikidata.org/entity/Q33839434

about

Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6 Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Interleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targeting The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways.Muscle oxidative capacity during IL-6-dependent cancer cachexia.Overload-induced skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6 Cancer cachexia, mechanism and treatment Interleukin 6 as a key regulator of muscle mass during cachexia Sex differences in the relationship of IL-6 signaling to cancer cachexia progression C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting Activation of the endoplasmic reticulum stress response in skeletal muscle of G93A*SOD1 amyotrophic lateral sclerosis mice.The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting.Plasma from septic shock patients induces loss of muscle protein.The effect of exercise on IL-6-induced cachexia in the Apc ( Min/+) mouse.Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease Rel A/p65 is required for cytokine-induced myotube atrophy.IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse.Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle.Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle.Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.Beneficial bacteria inhibit cachexia.Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans Increased expression of atrogenes and TWEAK family members after severe burn injury in nonburned human skeletal muscle.Mechanisms governing the health and performance benefits of exercise.Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia.A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.Effect of nandrolone decanoate administration on recovery from bupivacaine-induced muscle injury.Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetics in cancer cachexia.Developing models for cachexia and their implications in drug discovery.Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for Inflammation.Levosimendan affects oxidative and inflammatory pathways in the diaphragm of ventilated endotoxemic mice.Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90.Are there any benefits of exercise training in cancer cachexia?

P2860

Q26743557-24BA268F-F7C9-423E-A691-BFA25F3CE151 Q28068034-65AFC9ED-27AA-4D26-93F6-446988E17804 Q28566541-DA29D660-AB82-49C5-88ED-ADEC9658D7CF Q34031423-80ABCA75-4F99-45CE-93FD-B4734BA932DC Q34236379-669351F7-155D-441D-A321-3BA3B599EA7B Q34421809-C3A8ACA0-33AF-4F23-9352-55CB609790CC Q34598672-232BC783-A55C-43D4-805B-14BA62FA2AC6 Q34602991-DC0A9ED7-94E7-4E45-A322-BD58046E5707 Q34669440-C0E0C766-A6BC-474D-8F0B-04A06BB0EA4C Q34727530-D031C0B7-535F-4081-8A89-A92C948E07AF Q35214154-200B954E-0FDF-4787-BD68-FCFC63C174C2 Q35422257-B4247CBD-5DF4-4E26-A988-CBCA7073080F Q35617613-7B131A46-A438-4E90-94A7-0EBB172D1496 Q35671234-61AEACC8-16A9-4E72-A0FB-EB94F90FC578 Q35908213-F1038188-40DC-43FB-990A-9943B2EE15F7 Q36028206-71C1359B-160C-474E-A9D2-729CF4A5279E Q36095662-237ED29B-E7C1-40D1-9427-C13F568ED50F Q36114658-029930C5-18A4-4632-9B7D-A02CD588F54F Q36200582-850A360F-D2EA-4C55-80AD-52B166F889F9 Q36487406-CB2F33A2-8056-4C19-9C6E-ABE3FDB4923A Q36737744-960D78F8-9F00-466D-8908-932F5CA1E584 Q36836194-2452506D-61F5-4166-876E-38E5A9E995B0 Q36941459-3B7790D4-0F89-4B60-A793-7750F909EAB0 Q36945094-288EF1E5-9E33-4904-94D2-20A977DA720E Q37022010-413821C1-CA72-47C9-8F55-9DB91B7BBB9D Q37150772-CC90B663-DB08-43ED-B703-8629DAE67BFA Q37164742-6CB3AC23-E60B-4A75-9F51-9AC4672EAAC7 Q37337855-B9BFEE31-6C4B-4AD2-9148-E15EE881FA29 Q37392800-5FEB8506-FC33-4DB3-8C73-E52710C79256 Q37411666-2C21BCCE-AD2D-46FE-B6E7-25B8E784CD38 Q37422180-F44DEDD8-AB96-4462-B9B5-F4CFB6768A61 Q37644886-8471C69D-374B-44CF-909D-3FB0E5F2F451 Q37924325-0D2E93DE-33F8-4CA0-9E0A-DC5E1CDF9A99 Q38451282-3C4843FC-07CC-44F8-82E4-961B77BE8E23 Q38606110-DE099A02-F8B9-490A-8CEE-E340A969B36F Q40972142-78E6AFA7-CBE1-49D3-A6D0-3F22949991D0 Q41146515-3D241EA2-C503-4031-AF03-7FC41C63F05D Q41316270-CBCBF568-86D7-42B9-9B30-36EEA5AAFFB8 Q41701219-53CDB37D-0E74-44F8-BC59-201ED4DF554B Q42199742-E16B45E3-7211-43B9-83A8-B867BB2360A6

P2860

Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse

http://www.wikidata.org/entity/Q33839434

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@ast

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@en

type

label

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@ast

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@en

prefLabel

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@ast

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@en

P1433

Q33839434-6D6FF5A8-334C-4B40-BD7E-82CFE347977A

P1476

Q33839434-8E94DFC6-6724-4C80-A90F-4D774F872F63

P2093

Q33839434-0A035F95-5DB5-496A-A883-D358522B0846

Q33839434-621CEDA5-8228-43E8-BC61-C041B3E149A6

Q33839434-72A86203-119C-425D-9683-1C102D413AC9

Q33839434-C64B28F2-E827-44E0-A3DC-C8BC4C00A9C6

Q33839434-E2C57396-FBF1-474D-9DB1-70560101AA34

P2860

Q33839434-0ACC333C-F32F-4753-B25C-B27C7DC754E9

Q33839434-140AFDDC-92E9-45D1-A8D8-F5A49A45DA0B

Q33839434-1C4B0716-3017-4AAC-A761-27451354220B

Q33839434-2042F43C-D498-4616-9623-567977AC137B

Q33839434-2B8D9F83-CDB7-4FA7-AF92-4BB409BD4A6B

Q33839434-33E04638-D83B-4980-B608-56D88222302D

Q33839434-38127328-8AD3-4C98-AD72-DDB665972F46

Q33839434-40D7A0E4-1CE7-4988-8355-8D9911579B0D

Q33839434-4785EE3E-7386-421E-8E9C-21B4EA9C7FED

Q33839434-4E52DB26-D7C5-41B9-AD41-A631E5FD819B

P2888

Q33839434-25AC447B-3808-4C68-A7C6-8F9702B24F99

P304

Q33839434-5AFE281F-DCC0-421A-A99A-98BBC8DDEF82

P31

Q33839434-3F1708AC-5655-47D2-B957-DCD512E61617

P356

Q33839434-C95EFDEF-36A0-415D-8CDF-A4BFB86FC09E

P433

Q33839434-B8A40C64-F889-48CF-9E6F-6C8EC5687AF5

P478

Q33839434-D94C0894-9BF1-4880-8CAB-AA56DAA67F0B

P50

Q33839434-43488829-D749-40BD-BFC4-A87B59BF99E6

P577

Q33839434-4BDB071D-1895-4387-82DF-CC4DF17CD161

P5875

Q33839434-D85F3C6E-B3F2-4E2A-8F45-D35D6FA0BCBC

P6179

Q33839434-8F297D66-BE47-4B97-A2DB-D8B533729779

P698

Q33839434-A842B528-CF26-45D3-B8FB-D9D0CFD61305

P932

Q33839434-913AACD6-9016-4DDD-8DF4-45926C4E5F46

P356

S00424-008-0574-6

P1433

Pfluegers Archiv

P1476

Muscle wasting and interleukin ...... cachectic Apc ( Min/+ ) mouse

@en

P2093

Franklin G Berger

http://www.w3.org/2001/XMLSchema#string

J Mark Davis

http://www.w3.org/2001/XMLSchema#string

James P White

http://www.w3.org/2001/XMLSchema#string

Kristen A Baltgalvis

http://www.w3.org/2001/XMLSchema#string

Maria Marjorette O Peña

http://www.w3.org/2001/XMLSchema#string

P2860

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

The temporal responses of protein synthesis, gene expression and cell signalling in human quadriceps muscle and patellar tendon to disuse

Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3

The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

PGC-1alpha: a key regulator of energy metabolism

Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia

Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression

Identification of ubiquitin ligases required for skeletal muscle atrophy

P2888

s00424-008-0574-6

P304

989-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00424-008-0574-6

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

457

http://www.w3.org/2001/XMLSchema#string

P50

James A. Carson

P577

2008-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225487417

http://www.w3.org/2001/XMLSchema#string

P6179

1027003912

http://www.w3.org/2001/XMLSchema#string

P698

18712412

http://www.w3.org/2001/XMLSchema#string

P932

2867110

http://www.w3.org/2001/XMLSchema#string